Online citations, reference lists, and bibliographies.
← Back to Search

Vinorelbine And Gemcitabine As Second- Or Third-line Therapy For Malignant Pleural Mesothelioma.

M. Zauderer, S. L. Kass, K. Woo, C. Sima, M. Ginsberg, L. Krug
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVES Pemetrexed-cisplatin is the only FDA-approved regimen for malignant pleural mesothelioma (MPM), and the impact on survival is modest. No drugs have been shown to improve survival as second-line therapy, yet vinorelbine and gemcitabine are prescribed based on the results of small phase II trials. To augment the existing limited data, we examined our institutional experience with vinorelbine and gemcitabine in patients with previously treated MPM. MATERIALS AND METHODS We reviewed charts of patients with MPM treated with vinorelbine and/or gemcitabine as second- or third-line therapy between 2003 and 2010. Toxicity was graded according to the Common Terminology Criteria for Adverse Events Version 4.0. CT scans were reviewed with a reference radiologist according to modified RECIST criteria. RESULTS Sixty patients were identified: 33 treated with vinorelbine, 15 gemcitabine, and 12 both agents. Eighty-three percent initially received pemetrexed-platinum. Toxicity was substantial: 46% experienced at least one episode of grade 3-4 toxicity. Of 56 patients evaluable radiologically, there was 1 partial response (gemcitabine) giving a response rate of 2% (95% CI: 0-10%). Forty-six percent had stable disease. Median progression free survival was 1.7 months for vinorelbine and 1.6 months for gemcitabine. Median overall survival was 5.4 and 4.9 months, respectively. CONCLUSIONS Response to second- or third-line vinorelbine or gemcitabine is rare. The high rate of stable disease warrants the continued use of these agents in this setting, though the impact on survival is questionable. These data justify the choice of placebo control arms in randomized trials of novel agents in previously treated patients.
This paper references
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
L. Krug (2011)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma
S. Busacca (2012)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
J. Van Meerbeeck (1999)
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2001)
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)

This paper is referenced by
Consensus of the AustrianMesothelioma Interest Group (AMIG)
C. Geltner (2016)
Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment
C. Ban (2017)
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
M. Disselhorst (2019)
Traitement du mésothéliome pleural malin en 2016
A. Scherpereel (2016)
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
A. Guazzelli (2019)
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
C. Raynaud (2015)
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
M. Okada (2019)
Nivolumab for the treatment of unresectable pleural mesothelioma
K. Hotta (2019)
Radiation Therapy in Mesothelioma
J. Willmann (2019)
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
G. Ceresoli (2015)
How I treat malignant pleural mesothelioma
G. Viscardi (2020)
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
S. Dolly (2016)
Pleuramesotheliom beim alten und geriatrischen Patienten
Martin Steins (2018)
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
D. Cortinovis (2020)
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review
O. Abdel-Rahman (2015)
Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma
V. A. B. Lima (2015)
Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
J. Raphael (2014)
Molecular-Targeted Therapy For Malignant Mesothelioma
Y. Tada (2015)
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
L. Calabrò (2017)
Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
M. Awad (2016)
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
A. Billè (2016)
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future
A. Scherpereel (2017)
Advances in treatment of mesothelioma
C. Maggioni (2016)
Malignant Pleural Mesothelioma: The Last 8 Years of Experience in Our Area
V. Riveiro (2019)
Updates in the diagnosis and treatment of malignant pleural mesothelioma
D. Katzman (2018)
Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up†
P. Baas (2015)
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
M. Zauderer (2017)
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Y. Metaxas (2018)
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar